1,3,4-oxadiazole has been researched along with Cognitive Decline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seth, A; Sharma, P; Shrivastava, SK; Srivastava, P; Tripathi, PN | 1 |
| Gupta, SK; Krishnamurthy, S; Mishra, P; Seth, A; Sharma, P; Shrivastava, SK; Srivastava, P; Tripathi, A; Tripathi, PN | 1 |
2 other study(ies) available for 1,3,4-oxadiazole and Cognitive Decline
| Article | Year |
|---|---|
Design and development of novel N-(pyrimidin-2-yl)-1,3,4-oxadiazole hybrids to treat cognitive dysfunctions.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Design; Humans; Mice; Models, Molecular; Molecular Structure; Oxadiazoles; Pyrimidines; Structure-Activity Relationship | 2019 |
Design and development of 1,3,4-oxadiazole derivatives as potential inhibitors of acetylcholinesterase to ameliorate scopolamine-induced cognitive dysfunctions.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Animals; Avoidance Learning; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Development; Electrophorus; Horses; Humans; Male; Memory; Mice; Molecular Structure; Oxadiazoles; Peptide Fragments; Protein Aggregates; Scopolamine; Structure-Activity Relationship | 2019 |